Navigation Links
Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Date:10/13/2011

h a median PFS of 8.8 months in the bortezomib-relapsed population.  Median overall survival (OS) was 25 months.  Therapy was generally well-tolerated; toxicities, including gastrointestinal side-effects and fatigue, proved manageable.  No treatment-related mortality was seen.  

The investigators concluded that the combination of perifosine and bortezomib is active and well-tolerated in heavily pre-treated MM patients previously treated with bortezomib, and that the survival data in this study is encouraging, even in patients previously exposed to, and refractory to, bortezomib, as well as prior immunomodulatory drugs.

Data from this study was previously presented at the 2009 American Society of Hematology (ASH) conference.

A copy of the article featured in the current online edition of the Journal of Clinical Oncology can be obtained at http://jco.ascopubs.org/content/early/2011/10/04/JCO.2010.33.9788.full.pdf+html

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. (NASDAQ: AEZS) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colo
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
2. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
3. Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
4. Hepatitis C Phase 2A Trial Positive Results
5. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
6. Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
7. GeoVax Phase 2a Clinical Trial Completes Enrollment
8. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
9. Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial
10. Visual Healthcare to Supply Enabling Technology for Home Care Consortium Software and Support Revenues to Reach $17 M in Phase One
11. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 13, 2014 Auf ... Tokio veranstalteten F&E-Tagung meldete Astellas ... Neuausrichtung seines Forschungsrahmenprogramms. Die Tagung bot Astellas ... fortgeschrittenen klinischen Programme und die Konzernstrategie des ... bestand darin, aktuelle Meldungen zu den Astellas-Initiativen ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Technologies Transforming Consumer Marketing Research Playbook 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
(Date:7/14/2014)... July 14, 2014 — ... cloud management, governance, and compliance software solutions for ... will be available to customers of Rackspace, ... , The hosting and value-added reseller (VAR) agreements ... solutions to new or existing customers: , Backup: ...
(Date:7/14/2014)... July 14, 2014 “You've probably heard ... exactly does that mean?” This question was posed in ... on Western Washington Medical Group’s blog regarding how people ... health in mind . , According to the article, ... placing themselves at a high risk of dehydration and ...
(Date:7/14/2014)... Sometimes, thinking “inside the box” can be revolutionary. ... product release, Joyboxx™ - The world’s only hygienic and ... Inventor and CEO, Deborah Semer began designing a safe ... for their ‘toys’ after she realized no such product ... Semer met 30-year industry veteran Phyllis Heppenstall, the legendary ...
(Date:7/14/2014)... new analysis has found that rates of testicular cancer ... Hispanic American men, but not among their non-Hispanic counterparts. ... journal of the American Cancer Society, the findings indicate ... of testicular cancer in Hispanic adolescents and young adults, ... cause of this trend. , Testicular cancer is one ...
(Date:7/14/2014)... According to the Blood Pressure Solution book review recently ... a series of new information on high blood pressure ... can help readers understand more about blood pressure. The book ... methods to control hypertension naturally. , Blood ... penned by Ken Burge, a medical researcher and health consultant. ...
Breaking Medicine News(10 mins):Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3Health News:Drink With Your Mental Health in Mind, Advises an Article by Mental Health America Featured by Western Washington Medical Group 2Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:Testicular cancer rates are on the rise in young Hispanic Americans 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3
... and productivity , , TUESDAY, Sept. 25 (HealthDay News) -- ... program that used a care manager to guide them ... well as greater productivity. , The authors of the ... of the Journal of the American Medical Association ...
... of the Combat Soldiers Recovery Fund, announced that there ... Wednesday evening,September 26, 2007. According to Ms. Miller, "100% ... soldiers or their immediate family, with no,reductions for overhead ... "the Fund has distributed $70,000 so far,and is now ...
... of Boise,s Leadership in the ... Premium and Specialty Papers Market, BENSENVILLE, Ill., ... today announced that Boise(R) BEWARE(TM), an,anti-copy/anti-scan paper is in compliance ... The legislation,will go into affect on October 1, 2007. ...
... Life Sciences, LLC, an,Indiana based company, has introduced ... about the growing health risks associated,with diabetes. This ... and,antioxidant-rich dietary supplement that has been scientifically proven ... two conditions,that most often lead to Type II ...
... Experts in health care and,technology investment discussed objectives, ... growth in Ohio today at the Ohio,Capital Fund,s ... will help,shape Ohio,s future as it rebounds from ... the State of Ohio is changing," said Paul,Cohn ...
... open its doors to area ... youths on September 28, PORTLAND, Ore., Sept. 25 ... to play, learn and grow with,the grand opening of the Regence Boys & ... grant from Regence,the largest in the company,s history. The facility is Portland,s first,completely ...
Cached Medicine News:Health News:Treatment Programs Benefit Depressed Workers 2Health News:Treatment Programs Benefit Depressed Workers 3Health News:Boise(R) BEWARE(TM) Meets New Federal Guidelines Set Forth by Medicaid 2Health News:New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced 2Health News:New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced 3Health News:Experts Agree. Ohio's Technology Investment Future Looks Bright 2Health News:Experts Agree. Ohio's Technology Investment Future Looks Bright 3Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 2Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 3
... seamless eliminating the possibility of leakage around glued ... temperature resistant gel trays meaning you do no ... added user friendliness, the Primo tanks come with ... The Primo Gel Systems are designed to be ...
... up and safe to use, the Gel XL ... and running agarose gels. The unit is compact, ... power supply eliminates a tangled mess of leads ... Designed for safety and convenience, the power supply ...
... HE 33 Mini Submarine Unit for nucleic acid analysis ... designed for very fast separations of DNA restriction fragments ... a heat-sink. Fill the base with coolant and seal. ... keeping the unit in a freezer or by immersing ...
... 2000 apparatus and ready-to-use gels are the ... of nucleic acids by submerged gel electrophoresis. ... system, offering full compatibility and optimal performance, ... SEA 2000 and a unique staining tray, ...
Medicine Products: